Reaction
Cryptosporidiosis Infection reporting signals
As of the last recalculation, Cryptosporidiosis Infection appears in 519 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is CABOTEGRAVIR (PRR 135.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Cabotegravir | 26 | 135.9 | 136.3 |
| Tacrolimus Ointment 0.1% | 214 | 116.6 | 116.8 |
| Tacrolimus Extended-Release Capsules | 214 | 116.3 | 116.5 |
| Tacrolimus | 219 | 96.3 | 96.4 |
| Sirolimus | 27 | 84.7 | 84.9 |
| Mycophenolate Mofetil | 182 | 82.2 | 82.3 |
| Mycophenolate Mofetil Hydrochloride | 182 | 82.1 | 82.2 |
| Mycophenilic Acid | 34 | 70.3 | 70.5 |
| Basiliximab | 17 | 59.9 | 60.0 |
| Mycophenolic Acid | 39 | 52.8 | 52.8 |
| Micafungin Sodium | 10 | 48.2 | 48.3 |
| Valganciclovir Hydrochloride Powder, | 14 | 47.3 | 47.3 |
| Fludarabine Phosphate | 42 | 46.5 | 46.6 |
| Anti-Thymocyte Globulin (Rabbit) | 9 | 45.5 | 45.6 |
| Thiotepa | 8 | 34.1 | 34.1 |
| Lisdexamfetamine Dimesylate | 26 | 33.2 | 33.2 |
| Valganciclovir | 15 | 32.8 | 32.9 |
| Valganciclovir Hydrochloride | 15 | 32.8 | 32.9 |
| Everolimus Tablets | 12 | 29.4 | 29.4 |
| Abacavir Sulfate | 7 | 29.2 | 29.2 |
| Ganciclovir Sodium | 7 | 26.9 | 26.9 |
| Melphalan | 14 | 25.3 | 25.4 |
| Melphalan Hydrochloride | 15 | 24.7 | 24.7 |
| Posaconazole Delayed-Release | 6 | 22.2 | 22.2 |
| Efavirenz | 6 | 21.8 | 21.8 |
| Busulfan | 8 | 20.7 | 20.7 |
| Ixazomib | 10 | 14.2 | 14.2 |